



## ASX Release

EMvision Medical Devices Ltd  
ACN 620 388 230  
Level 10, 12 Creek Street,  
Brisbane Qld 4000  
02 8667 5337  
contact@emvision.com.au

# EMVISION APPOINTS HEAD OF PROGRAM MANAGEMENT

**EMvision Medical Devices Limited (ASX: EMV) (“EMvision” or the “Company”)** is pleased to announce that it has strengthened its organisational capability with the appointment of medical device program management expert, Forough Khandan, in the role of Head of Program Management for EMVision.

Forough was previously Program Manager at Nanosonics (ASX:NAN), reporting directly to the CTO, where she led a large multi-disciplined team of engineers and scientists across the business.

During her 9-year tenure at Nanosonics, Forough successfully planned and executed highly complex new product development programs and was key in leading activities required to define, develop and deliver Nanosonics' second generation of trophon device from prototype through to after-market release. Forough was also responsible for specific strategic partnerships and engagement programs.

Reporting to the CEO, Forough will lead and drive the execution of EMVision's product program across the commercialisation pathway integrating the key business components to meet international medical device standards. Forough will also provide guidance on the establishment of EMVision's manufacturing strategy and processes associated with the establishment of manufacturing capability.

CEO Dr Ron Weinberger said; “I am thrilled to have Forough join our team. At EMVision we are focussed on project and product execution and Forough has tremendous depth in this area. Her results at Nanosonics speak for themselves and her expertise in global regulatory standards and requirements for getting product to market is an important reason why I have chosen her for this instrumental role. Forough lived through the early development of Nanosonics and brings the agility of thinking required to help bring an early stage company to a successful leader in the medical device sector.”

### [ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills  
Investor & Media Relations  
+61 468 385 208  
michael@spring-communications.com.au

Scott Kirkland  
Executive Director  
+61 2 8667 5337  
skirkland@emvision.com.au

## About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.9 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

## Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.